Home
About Us
About ReNeuron
Board of Directors
Senior Management
Advisory Board
Working at ReNeuron
Patents
Exosomes
iPSC
Partnering
Existing Partnerships & Collaborations
News
Investors
Investor Centre
Corporate Governance
Share Price Information
Major Shareholdings
Advisors
Analyst Research
Webcasts and Presentations
Financial Reports
General Meetings
Financial Calendar
Email alerts
RNS Notifications
Documents and Circulars
AIM Rule 26
Declarations
Contact
Contact Us
Home
About Us
About ReNeuron
Board of Directors
Senior Management
Advisory Board
Working at ReNeuron
Patents
Exosomes
iPSC
Partnering
Existing Partnerships & Collaborations
News
Investors
Investor Centre
Corporate Governance
Share Price Information
Major Shareholdings
Advisors
Analyst Research
Webcasts and Presentations
Financial Reports
General Meetings
Financial Calendar
Email alerts
RNS Notifications
Documents and Circulars
AIM Rule 26
Declarations
Contact
Contact Us
Presentations: Phase I clinical trial in stroke disability (PISCES)
CFO Michael Hunt Presents at Shares Magazine Investor Evening – 27th October 2016
CEO Presents at the 6th Annual Cell & Gene Partnering Forum on the Mesa 2016
CEO Presents at Cell & Gene Therapy Investor Day March 2016
Section: News
News
News Archive
Events
Filter by:
Corporate
Product
Induced pluripotent stem cell (iPSC) Platform
CTX cells for Stroke Disability
CTX cells for Critical Limb Ischaemia
hRPCs for Retinitis Pigmentosa
CTX-derived Exosomes
Trial
Phase III clinical trial in stroke disability (PISCES-III)
Phase I clinical trial in stroke disability (PISCES)
Phase II clinical trial in stroke disability (PISCES-II)
Observational study in stroke
Phase I trial in critical limb ischaemia
Phase I/II clinical trial in retinitis pigmentosa
